Metabolite elucidation of the Hsp90 inhibitor SNX-2112 using ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS)

Xenobiotica

Volumn 44, Issue 5, 2014, Pages 455-464

  Liu, Wei ^a   Liu, Hongming ^a   Sun, Hua ^a   Dong, Dong ^a   Ma, Zhiguo ^a   Wang, Yifei ^a   Wu, Baojian ^a  

^a JINAN UNIVERSITY   (China)

Author keywords

Anti cancer drug; CYP metabolism; Metabolynx; SNX 2112; UPLC QTOF MS

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; HEAT SHOCK PROTEIN 90 INHIBITOR; SNX 2112; UNCLASSIFIED DRUG; CYP1A1 PROTEIN, HUMAN; CYP2F1 PROTEIN, HUMAN; CYTOCHROME P450 2D6; FUSED HETEROCYCLIC RINGS;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FECES ANALYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; QUADRUPOLE MASS SPECTROMETRY; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; URINALYSIS; ANIMAL; BLOOD; CHEMISTRY; DRUG EFFECTS; DRUG INACTIVATION; FECES; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; PROCEDURES; SPRAGUE DAWLEY RAT; URINE;

ANIMALS; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; FECES; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; INACTIVATION, METABOLIC; INTESTINES; MASS SPECTROMETRY; MICROSOMES, LIVER; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84898712261     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2013.853849     Document Type: Article

References (36)

1. Bachleitner-Hofmann T, Sun MY, Chen CT, et al. (2011). Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET inhibition. Clin Cancer Res 17:122-33.
2. Barta TE, Veal JM, Rice JW, et al. (2008). Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90. Bioorg Med Chem Lett 18:3517-21.
3. Bateman KP, Castro-Perez J, Wrona M, et al. (2007). MSE with mass defect filtering for in vitro and in vivo metabolite identification. Rapid Commun Mass Spectrom 21:1485-96.
4. Castro-Perez JM. (2007). Current and future trends in the application of HPLC-MS to metabolite-identification studies. Drug Discov Today 12:249-56.
5. Chandarlapaty S, Sawai A, Ye Q, et al. (2008). SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res 14:240-8.
6. Chinn DC, Holland WS, Yoon JM, et al. (2012). Anti-tumor activity of the HSP90 inhibitor SNX-2112 in pediatric cancer cell lines. Pediatr Blood Cancer 58:885-90.
7. Csermely P, Schnaider T, Soti C, et al. (1998). The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther 79:129-68.
8. Deng P, You T, Chen X, et al. (2011). Identification of amiodarone metabolites in human bile by ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry. Drug Metab Dispos 39:1058-69.
9. Deng P, Zhong D, Yu K, et al. (2013). Pharmacokinetics, metabolism, and excretion of the antiviral drug arbidol in humans. Antimicrob Agents Chemother 57:1743-55.
10. Ding J, Chen X, Gao Z, et al. (2013). Metabolism and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor apatinib in humans. Drug Metab Dispos 41: 1195-210.
11. Dong D, Wu B, Chow D, Hu M. (2012). Substrate selectivity of drug-metabolizing cytochrome P450s predicted from crystal structures and in silico modeling. Drug Metab Rev 44: 192-208.
12. Gong A, Chen X, Deng P, Zhong D. (2010). Metabolism of flumatinib, a novel antineoplastic tyrosine kinase inhibitor, in chronic myelogenous leukemia patients. Drug Metab Dispos 38:1328-40.
13. Hallifax D, Houston JB. (2006). Binding of drugs to hepatic microsomes: comment and assessment of current prediction methodology with recommendation for improvement. Drug Metab Dispos 34:724-46.
14. Huang KH, Veal JM, Fadden RP, et al. (2009). Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J Med Chem 52: 4288-305.
15. Liu H, Ma Z, Wu B. (2013). Structure-activity relationships and in silico models of P-glycoprotein (ABCB1) inhibitors. Xenobiotica 43:1018-26.
16. Liu KS, Ding WC, Wang SX, et al. (2012a). The heat shock protein 90 inhibitor SNX-2112 inhibits B16 melanoma cell growth in vitro and in vivo. Oncol Rep 27:1904-10.
17. Liu KS, Liu H, Qi JH, et al. (2012b). SNX-2112, an Hsp90 inhibitor, induces apoptosis and autophagy via degradation of Hsp90 client proteins in human melanoma A-375 cells. Cancer Lett 318:180-8.
18. Mortishire-Smith RJ, Castro-Perez JM, Yu K, et al. (2009). Generic dealkylation: a tool for increasing the hit-rate of metabolite rationalization, and automatic customization of mass defect filters. Rapid Commun Mass Spectrom 23:939-48.
19. Nassar AE, Talaat RE. (2004). Strategies for dealing with metabolite elucidation in drug discovery and development. Drug Discov Today 9: 317-27.
20. Neckers L, Neckers K. (2005). Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics: an update. Expert Opin Emerg Drugs 10: 137-49.
21. Okawa Y, Hideshima T, Steed P, et al. (2009). SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood 113: 846-55.
22. Palmeira A, Sousa E, Vasconcelos MH, et al. (2012a). Structure and ligand-based design of P-glycoprotein inhibitors: a historical perspective. Curr Pharm Des 18:4197-214.
23. Palmeira A, Sousa E, Vasconcelos MH, Pinto MM. (2012b). Three decades of P-gp inhibitors: skimming through several generations andscaffolds. Curr Med Chem 19:1946-2025.
24. Rajan A, Kelly RJ, Trepel JB, et al. (2011). A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res 17:6831-9.
25. Ramanathan R, Jemal M, Ramagiri S, et al. (2011). It is time for a paradigm shift in drug discovery bioanalysis: from SRM to HRMS. J Mass Spectrom 46:595-601.
26. Ranasinghe A, Ramanathan R, Jemal M, et al. (2012). Integrated quantitative and qualitative workflow for in vivo bioanalytical support in drug discovery using hybrid Q-TOF-MS. Bioanalysis 4: 511-28.
27. Walsh AA, Szklarz GD, Scott EE. (2013). Human cytochrome P450 1A1 structure and utility in understanding drug and xenobiotic metabolism. J Biol Chem 288:12932-43.
28. Wang R, Shao F, Liu Z, et al. (2013). The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-kB and disruption of mitochondria-dependent pathways. Chem Biol Interact 205:1-10.
29. Wang SX, Ju HQ, Liu KS, et al. (2011). SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells. Biosci Biotechnol Biochem 75:1540-5.
30. Wrona M, Mauriala T, Bateman KP, et al. (2005). 'All-in-one' analysis for metabolite identification using liquid chromatography/hybrid quadrupole time-of-flight mass spectrometry with collision energy switching. Rapid Commun Mass Spectrom 19:2597-602.
31. Xie C, Zhong D, Yu K, Chen X. (2012). Recent advances in metabolite identification and quantitative bioanalysis by LC-Q-TOF MS. Bioanalysis 4:937-59.
32. Xie C, Zhou J, Guo Z, et al. (2013). Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol 168:1687-706.
33. Ye L, Wang T, Yang C, et al. (2011). Microsomal cytochrome P450-mediated metabolism of hypaconitine, an active and highly toxic constituent derived from Aconitum species. Toxicol Lett 204: 81-91.
34. Zhai QQ, Gong GQ, Liu Z, et al. (2011). Preclinical pharmacokinetic analysis of SNX-2112, a novel Hsp90 inhibitor, in rats. Biomed Pharmacother 65:132-6.
35. Zhang NR, Yu S, Tiller P, et al. (2009). Quantitation of small molecules using high-resolution accurate mass spectrometers-a different approach for analysis of biological samples. Rapid Commun Mass Spectrom 23:1085-94.
36. Zhou J, Tracy TS, Remmel RP. (2010). Glucuronidation of dihydrotestosterone and trans-androsterone by recombinant UDP- glucuronosyltransferase (UGT) 1A4: evidence for multiple UGT1A4 aglycone binding sites. Drug Metab Dispos 38: 431-40.